China Diabetes Registry by Metabolic Management Center

Launched by GUANG NING · Jan 17, 2019

Keywords

ClinConnect Summary

The China Diabetes Registry by the Metabolic Management Center is a clinical trial designed to better understand and manage diabetes and its related conditions. This study aims to create a nationwide database that collects information about diabetes patients, including their health data and biological samples. By doing this, researchers hope to explore how diabetes affects people, identify new risk factors, and find better ways to treat the disease and its complications. The trial is part of a broader effort to improve diabetes care in China through advanced data analysis and to support the country's health goals for 2030.

To participate in this study, individuals must be at least 18 years old and have a diagnosis of diabetes, either through self-reporting or by a clinician. Both men and women can join, provided they agree to participate and follow the study guidelines. Participants can expect to have their health monitored over time, and their experiences will help evaluate treatment strategies and the overall quality of diabetes care. It's important to note that individuals with certain serious health conditions or infections may not be eligible to participate.

Gender

ALL

Eligibility criteria

• Main Inclusion Criteria:
• • Age ≥ 18 years old
• • Diagnosis of diabetes mellitus based on self-reported history of diagnosed diabetes by clinicians or in line with the current domestic diagnostic criteria for diabetes
• • Gender: males and females
• • Provide written informed consent
• • Satisfactory compliance
• Main Exclusion Criteria:
• • Patients with significantly reduced life expectancy (less than 5 years)
• • With Drug abuse
• • With AIDS or syphilis or infectious diseases such as viral hepatitis or tuberculosis in active phase at enrollment